TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04685616

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved site radiotherapy
Description: Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines.~Recommended dose 30Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved site radiotherapy
Description: Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines.~Recommended dose 30Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: See arm description
Study: NCT05254548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-539313
Description: 100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
Study: NCT05508503

Intervention type: DIAGNOSTIC_TEST
Intervention: Test of methylated NTMT1 and MAP3K14-AS1
Description: A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Test of methylated NTMT1 and MAP3K14-AS1
Description: A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT
Description: Fecal immunochemical test（optional）

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT
Description: Fecal immunochemical test（optional）
Study: NCT04685616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: See arm description
Study: NCT05783154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue-Derived Mesenchymal Stem Cell
Description: After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule.~Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle
Study: NCT05417555

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Focused Ultrasound Pulsation (LIFUP)
Description: Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Focused Ultrasound Pulsation (LIFUP)
Description: Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Focused Ultrasound Pulsation (LIFUP)
Description: Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)
Study: NCT04685616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: See arm description
Study: NCT05151835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K2 Robotic Surgical System
Description: The K2 Robotic Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery in the thorax and abdomen. The K2 Robotic Surgical System consists of a Surgeon Console \[SGC\], a Patient Side Robot \[PSR\], and a Vision Cart \[VCT\], and is used with an endoscope, Surgical Instruments \[SGI\], and Accessories \[ACC\]. The surgeon views the three-dimensional endoscopic image on a High-Resolution Stereo Viewer (3D Viewer), which provides a view of the abdominal cavity and surgical instrumentation, along with icons and other user interface features.
Study: NCT04685616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haematopoietic growth factor
Description: See arm description
Study: NCT05704348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy with gastropexy
Description: Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.
Study: NCT06546410

Intervention type: DEVICE
Intervention: BioEP
Description: All patient's EEG will have the BioEP score conducted on it

Intervention type: DEVICE
Intervention: BioEP
Description: All patient's EEG will have the BioEP score conducted on it
Study: NCT05704348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy without gastropexy
Description: Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.
Study: NCT06346314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular retraction exercise
Description: Participant lies prone with hands superior to the head on a treatment plinth and lifts their elbows 10 repetitions for three sets with 30 seconds of rest between each set.
Study: NCT06038357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBITS
Description: The CBITS program is a skills-based group and individual intervention, which uses evidence-based cognitive-behavioral techniques (e.g. psychoeducation, relaxation, social problem solving, cognitive restructuring, and exposure) and is designed for delivery by mental health professionals. The program consists of 10 45-minute group sessions (about 6-8 students/participants per group), 1-3 individual sessions, 2 parent/caregiver psychoeducational sessions, and 1 teacher/ child welfare staff educational session. For this study, we will specifically train and supervise study therapists to deliver the intervention within child welfare programs.
Study: NCT05339932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Wheelchair Skills Training
Description: The intervention involves manual wheelchair skills training.
Study: NCT06038357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU+
Description: In the control condition (TAU+), child welfare programs will follow their usual procedures (i.e. routine care of child welfare, referral to medical practitioners and psychotherapists, handling of prescribed medication, referral to inpatient treatments in case of risk to self and others) which reflects treatment as usual in child welfare programs and the mental health care system in Germany. Additionally, participants in the control condition will receive the same baseline assessment and reporting of screening results as participants in the treatment condition after each assessment.
Study: NCT05417555

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-Intensity Focused Ultrasound Pulsation (LIFUP)
Description: Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)
Study: NCT05381259

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: hortitherapy in people living with Alzheimer's taking place in three different day care
Description: 6 users benefiting from the horticultural workshop and 6 others from a usual workshop (control group) This control group will benefit from its usual workshop while the other group will participate in the horticultural workshop.~If it is impossible to carry out the workshops outdoors (rain or high heat), the day reception centers will provide a room to allow the workshops to be carried out. They will be adapted in terms of activities and materials.
Study: NCT04734990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seclidemstat
Description: Given PO
Study: NCT05200182

Intervention type: DEVICE
Group type: OTHER
Intervention: Neurofeedback with functional near infra-red spectroscopy
Description: the neurofeedback protocol will last 15 minutes per session, and during each session, the volunteer will have to increase the brain activity of his/her dorsolateral prefrontal cortex using a visual gauge representing the activity level of his/her own dorsolateral prefrontal cortex. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback with functional near infra-red spectroscopy
Description: the neurofeedback protocol will last 15 minutes per session, and during each session, the volunteer will have to increase the brain activity of his/her dorsolateral prefrontal cortex using a visual gauge representing the activity level of his/her own dorsolateral prefrontal cortex. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Neurofeedback
Description: the participants will receive the same instruction but will be shown a random signal

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: oral microbiota collection
Description: an examination and oral swab for oral microbiota analysis will be performed by a dentist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral microbiota collection
Description: an examination and oral swab for oral microbiota analysis will be performed by a dentist

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Description: questionnaires for pre-intervention behavioral characterization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: questionnaires for pre-intervention behavioral characterization
Study: NCT06248814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04536090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin (IQC-950AN)
Description: Isoquercetin will be administered by mouth twice daily for 28 days
Study: NCT05200182

Intervention type: DEVICE
Group type: OTHER
Intervention: resting-state fMRI
Description: characterize the brain function of volunteers by resting-state fMRI

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: resting-state fMRI
Description: characterize the brain function of volunteers by resting-state fMRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resting-state fMRI
Description: characterize the brain function of volunteers by resting-state fMRI

Intervention type: DEVICE
Group type: OTHER
Intervention: Electro gastrogram
Description: Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electro gastrogram
Description: Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro gastrogram
Description: Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.
Study: NCT06465615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-education with dichoptic reading on tablet
Description: Intervention 25 min/day, 5 days a week for 6 weeks at home (125-minute weekly load), under the supervision of a parent, on a dichoptic reading application on a loaned digital tablet, wearing anaglyph glasses provided and the patient's optical correction (if applicable).~During the first half of treatment (first 3 weeks), dichoptic separation takes place at the word level, and during the second half of treatment (last 3 weeks), it takes place at the individual letter level to promote precise eye alignment. This shift from dichoptic separation at word level to letter level increases the difficulty of the task. The text is freely chosen by the child and parent from a bank of age-appropriate books.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthoptic rehabilitation
Description: Conventional orthoptic rehabilitation consisting of 12 x 25-minute sessions twice a week over 6 weeks, carried out with an orthoptist from Montpellier University Hospital, combined with reinforcement exercises to be carried out at home for 15 minutes a day under parental supervision, 5 days a week (125-minute weekly load). This is the standard orthoptic treatment offered in France to patients with symptomatic convergence insufficiency, according to orthoptic procedures (10-15 sessions of the order of 20-25 minutes and 10-15 minutes of daily reinforcement exercises at home).
Study: NCT05200182

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Emotional Stroop task
Description: an emotional Stroop task adapted to food and body image representation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Stroop task
Description: an emotional Stroop task adapted to food and body image representation
Study: NCT04764981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essence oils
Description: Consists in olfactory training using essence oils
Study: NCT05834114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mckenzie protocol
Description: In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Stabilization technique
Description: In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
Study: NCT06006988

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: myoton pro
Description: MyotonPRO is a mobile, removable handheld myotonometer. This tool is noninvasive and provides a quantitative assessment of a muscle's viscoelastic properties. These properties are characterized by various parameters such as hardness, tone and elasticity. The probe of MyotonPRO delivers a short (15 ms), low intensity (0.58 N) mechanical impact/impact on the skin on the muscle. The response of the touch then generates a recorded signal and an internal software program generates an acceleration graph. Measurements of various viscoelastic muscle properties such as stiffness, tone and elasticity are then extracted from this graph.
Study: NCT05127525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-101
Description: IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
Study: NCT04793906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron supplement with a lunch meal containing beef
Description: Participants will consume a lunch meal containing beef with an iron supplement for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron supplement with a lunch meal containing plant-based alternative
Description: Participants will consume a lunch meal containing plant-based alternative with an iron supplement for 8 weeks.
Study: NCT06273943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Tablets, for oral use.
Description: Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.
Description: Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use
Description: * Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~* On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal Biopsies
Description: This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Biopsies
Description: This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm.
Study: NCT05955365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor
Description: The choice of P2Y12 inhibitor is left at investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Y12 inhibitor
Description: The choice of P2Y12 inhibitor is left at investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is administered for up to 1 month after PCI at investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOAC
Description: The choice of DOAC is left at investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOAC
Description: The choice of DOAC is left at investigator's discretion.
Study: NCT05343819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AON-D21
Description: AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic glucose solution identical in appearance to AON-D21.
Study: NCT05400226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGT-309
Description: VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.